KLOW BlendCheck methods and identity
What the 2026 Single Ingredient Policy Means for the KLOW Label
2 numbered sourcesSource years 2026
A peptide is a short amino-acid chain held together by peptide bonds. In a blend, several chains or complexes may be named on one label. The KLOW catalog entry refers here to BPC-157, TB-500, KPV and GHK-Cu. Several of those names appear in a 2026 federal policy on peptide substances. The policy's terms make it useful for understanding the difference between a named ingredient and a combined product. [1, 2]
The Department of Health and Human Services described limited circumstances under which it does not intend to take certain enforcement actions regarding compounding with specific listed bulk substances. The conditions include a product with a single listed active ingredient. The document explains that single-ingredient use helps make it easier to attribute an unexpected result or adverse event to a particular material. A four-component blend is not the single active ingredient arrangement described in that policy. [1]
This distinction matters even when no regulatory question is being asked. If four ingredients are present at the same time and one measurement changes, the result may reflect one ingredient, a combination of them or other aspects of the preparation. Comparing matched groups can help identify which material contributes to the result. An administrative decision about a defined substance does not make that scientific comparison. [1, 2]
The 2026 policy does not announce FDA approval of KLOW or establish that it is effective for any condition. It is a primary source for the scope of the interim enforcement approach. Evidence about the combined material's effects in people would have to come from separate studies of the exact combination.
Sources
Original works cited in this article. Links open the external record in a new tab.
